Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Imedex, Mechanisms in Medicine and Cornerstones launch new YouTube ‘You and IBD’

Cornerstones Health Inc., a nonprofit organization working to improve communication between patients with inflammatory bowel disease (IBD) and physicians who treat IBD, in collaboration with Imedex, LLC and Mechanisms in Medicine Inc., announced the launch of the new YouTube "You and IBD" - Animated IBD Patient Channel.

18 May 2012

Top-line results from Takeda vedolizumab phase 3 trial on Crohn's disease

Takeda Pharmaceutical Company Limited today announced top-line results from the international, randomized, placebo-controlled, double-blind GEMINI II pivotal phase 3 trial. The trial evaluated vedolizumab in 1,115 patients with moderately to severely active Crohn's disease who have failed at least one conventional therapy, including TNFα antagonists.

11 May 2012

Salix first quarter total product revenue increases 62% to $171.1M

Salix Pharmaceuticals, Ltd. today announced financial and operating results for the first quarter ended March 31, 2012 and other business updates.

8 May 2012

Lexicon first quarter revenues decrease 50% to $0.3 million

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months ended March 31, 2012.

3 May 2012

Enrollment complete in Zalicus Synavive Phase 2b clinical trial for rheumatoid arthritis

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced it has completed enrollment with 292 patients enrolled in the SYNERGY trial, a Phase 2b clinical trial designed to evaluate the safety and efficacy of Synavive, a low-dose glucocorticoid with the potential for amplified immuno-inflammatory benefits, in patients with rheumatoid arthritis (RA).

30 Apr 2012

InDex Pharmaceuticals granted U.S. patent for novel treatment of steroid-resistant inflammation

InDex Pharmaceuticals today announced that it has been granted a patent by the United States Patent and Trademark Office. The patent provides additional protection for the use of Kappaproct® and additional DNA-based immunomodulatory sequences (DIMS) for the treatment of steroid-resistant inflammatory diseases including inflammatory bowel disease, rheumatoid arthritis, psoriasis, asthma, emphysema and chronic obstructive pulmonary disease.

26 Apr 2012

Study: hUC-MSCs reduce inflammation that causes colitis

When laboratory mice were modeled with colitis and treated with human umbilical cord-derived mesenchymal cells, the cells homed in on the inflamed colon and effectively ameliorated colitis, reported a study published in a recent issue of Cell Transplantation.

24 Apr 2012

DDW to be held May 19-22 in San Diego

Thousands of physicians, researchers and academics from around the world will gather in San Diego in May for Digestive Disease Week- (DDW), the premiere scientific conference in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.

6 Apr 2012

Top-line results from Shire's SPD476 phase 3 trial on diverticulitis

Shire plc, the global specialty biopharmaceutical company, today announced top-line results of the PREVENT2 trial, a phase 3 investigational study of once-daily SPD476, MMX mesalamine in patients with a history of diverticulitis.

31 Mar 2012

Researchers develop gut-on-a-chip microdevice

Researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University have created a gut-on-a-chip microdevice lined by living human cells that mimics the structure, physiology, and mechanics of the human intestine-even supporting the growth of living microbes within its luminal space.

28 Mar 2012

Pannexins may contribute to symptoms related to IBD

Researchers from the Hotchkiss Brain Institute (HBI) and the Snyder Institute for Chronic Diseases at the University of Calgary's Faculty of Medicine have discovered a pathway that may contribute to the symptoms related to Crohn's disease and ulcerative colitis, collectively known as Inflammatory Bowel Disease.

22 Mar 2012

Study finds higher death rate in calorie-restricted models of IBD

In a surprising result, Michigan State University researchers looking at the effects of diet on bowel disease found that mice on a calorie-restricted diet were more likely to die after being infected with an inflammation-causing bacterial pathogen in the colon.

21 Mar 2012

Lexicon receives FDA Orphan Drug designation for telotristat etiprate to treat carcinoid syndrome

Lexicon Pharmaceuticals, Inc., announced today that the U.S. Food and Drug Administration (FDA) has granted its request for Orphan Drug designation for telotristat etiprate (LX1032) for the treatment of carcinoid syndrome.

21 Mar 2012

New information on efficacy of CLA in treating Crohn's disease

The Nutritional Immunology and Molecular Medicine Laboratory (NIMML) research team at Virginia Tech has discovered important new information on the efficacy of conjugated linoleic acid (CLA) in treating Crohn's disease, a form of inflammatory bowel disease (IBD). CLA is a naturally occurring acid found in meat and dairy products known for its anti-cancer and immune modulatory properties.

20 Mar 2012

NIH awards Avaxia $1.5M Phase II SBIR grant to develop antibody therapeutic for IBD

Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics for the treatment of gastrointestinal diseases, is proud to announce that it has received a second round of funding from the National Institutes of Health for its work in inflammatory bowel disease.

19 Mar 2012

Many children with Crohn's disease and IBD benefit from ImproveCareNow

Many children with Crohn's disease and ulcerative colitis who received treatment through ImproveCareNow, a national quality improvement and research network, ceased to have symptoms and no longer needed to take steroids for disease management.

13 Mar 2012

Dr. Falk Pharma, Lipid Therapeutics enter license agreement for LT-02 to treat UC

Dr. Falk Pharma GmbH and Lipid Therapeutics, a biotechnology company focused on novel treatments for inflammatory bowel disease, today announced that they have entered into a licensing agreement for the European rights to Lipid Therapeutics' lead product, LT-02, for ulcerative colitis.

8 Mar 2012

Santarus fourth quarter total revenues increase 65% to $42.6M

Santarus, Inc. (NASDAQ: SNTS) today reported financial and operating results for the three and 12 month periods ended December 31, 2011.

5 Mar 2012

BioLineRx granted Israeli approval for BL-7040 Phase II clinical trial for IBD

BioLineRx a biopharmaceutical development company, announced today that it has received approval from the Israeli Ministry of Health for commencing a Phase II clinical trial of BL-7040, an orally available molecule for treating Inflammatory Bowel Disease (IBD).

5 Mar 2012

Study: Diabetes may begin in the gut

Scientists at Washington University School of Medicine in St. Louis have made a surprising discovery about the origin of diabetes. Their research suggests that problems controlling blood sugar - the hallmark of diabetes - may begin in the intestines.

15 Feb 2012

Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Imedex, Mechanisms in Medicine and Cornerstones launch new YouTube ‘You and IBD’

Top-line results from Takeda vedolizumab phase 3 trial on Crohn's disease

Salix first quarter total product revenue increases 62% to $171.1M

Lexicon first quarter revenues decrease 50% to $0.3 million

Enrollment complete in Zalicus Synavive Phase 2b clinical trial for rheumatoid arthritis

InDex Pharmaceuticals granted U.S. patent for novel treatment of steroid-resistant inflammation

Study: hUC-MSCs reduce inflammation that causes colitis

DDW to be held May 19-22 in San Diego

Top-line results from Shire's SPD476 phase 3 trial on diverticulitis

Researchers develop gut-on-a-chip microdevice

Pannexins may contribute to symptoms related to IBD

Study finds higher death rate in calorie-restricted models of IBD

Lexicon receives FDA Orphan Drug designation for telotristat etiprate to treat carcinoid syndrome

New information on efficacy of CLA in treating Crohn's disease

NIH awards Avaxia $1.5M Phase II SBIR grant to develop antibody therapeutic for IBD

Many children with Crohn's disease and IBD benefit from ImproveCareNow

Dr. Falk Pharma, Lipid Therapeutics enter license agreement for LT-02 to treat UC

Santarus fourth quarter total revenues increase 65% to $42.6M

BioLineRx granted Israeli approval for BL-7040 Phase II clinical trial for IBD

Study: Diabetes may begin in the gut

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Empowering genomics research with cloud-based innovation

Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Empowering genomics research with cloud-based innovation

Newsletters you may be interested in